CeBIL is international and interdisciplinary. Anchored at the Faculty of Law, the Centre is led by founding director Professor Timo Minssen. CeBIL collaborates with key national and international experts from academia, public bodies, patient organizations and industry. Some of the most renowned international academic capacities in bioscience innovation law are involved in the Inter-CeBIL Program as either Core Partners or Collaborators. The Core Partners of the Inter-CeBIL Program are listed below.

Centre for Advanced Studies in Biomedical Innovation Law (CeBIL) at the Faculty of Law

Principal Investigator Professor Timo Minssen  and his Inter-CeBIL Copenhagen Team contribute with legal expertise in areas such as regulatory law, intellectual property law, data protection law, ethical and legal challenges of AI, big data in healthcare, quantum technology, biosolutions, and antimicrobial resistance (AMR).
Centre for Law, Medicine and Life Sciences, University of Cambridge

The Director of LML, Professor Kathleen Liddell contributes with expertise in intellectual property rights, patents and regulation of medicine and emerging medical technologies.

Professor Mateo Aboy (Director of Research) contributes expertise in engineering, patent law, data protection law, empirical IP research and regulatory science with a specific focus on advanced medical devices, AI and quantum computing (Inter-CeBIL Study 1).

Department of Health Technology, Technical University of Denmark

Head of Section , Professor Ole Lund contributes with expertise in health bioinformatics, machine learning, artificial intelligence and personalised medicine.
Petrie-Flom Center for Health Law Policy, Biotechnology & Bioethics, Harvard Law School

Faculty Director, Professor I. Glenn Cohen contributes with expertise on the intersection of bioethics/medical ethics and the law with a specific focus on big data, policy and translational medicine.